Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dostarlimab in cART Refractory HIV-Associated Kaposi Sarcoma
NCT05646082Phase 1Active, not recruiting
- Sponsor
- Imperial College London
- Start
- May 2023
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of dostarlimab in Kaposi sarcoma (KS), sponsored by Imperial College London. Primary endpoint: Treatment-Emergent Adverse Events. Started May 2023; status: active, not recruiting.
02
Drugs
dostarlimab
03
Conditions
Kaposi sarcoma (KS)
Beyond the preview
Go deeper on NCT05646082.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05646082.